Mesenchymal stem cell therapy (MD Anderson Cancer Center)

N/A

Report date: 2025/03/27 15:16:24

Base Information

Drug NameMesenchymal stem cell therapy (MD Anderson Cancer Center)
Drug Alias NameMSC-INFbeta
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursRespiratory Distress Syndrome, Adult +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursRespiratory Distress Syndrome, Adult +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A